Maze Therapeutics, Inc. Common Stock (MAZE) — Financial Flexibility Index
Maze Therapeutics, Inc. Common Stock (MAZE) has a Financial Flexibility Index of -0.19x as of June 2026. Free cash flow of $-14.95 Million (operating CF $-15.05 Million minus capex $107.00K) represents 0% of total liabilities ($78.50 Million). Check cash flow reinvestment rate of Maze Therapeutics, Inc. Common Stock to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Maze Therapeutics, Inc. Common Stock Financial Flexibility Index (2022–2025)
Historical Financial Flexibility Index trend for Maze Therapeutics, Inc. Common Stock across 4 annual periods. For the full cash flow conversion analysis, see Maze Therapeutics, Inc. Common Stock (MAZE) cash conversion ratio.
Annual Financial Flexibility Index for Maze Therapeutics, Inc. Common Stock (2022–2025)
Year-by-year free cash flow to debt coverage for Maze Therapeutics, Inc. Common Stock. Explore MAZE debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.64x | $-111.15 Million | $-111.94 Million | $42.16 Million | ▼ -249.2% |
| 2024 | 1.77x | $77.10 Million | $75.95 Million | $43.64 Million | ▲ +225.7% |
| 2023 | -1.41x | $-86.39 Million | $-86.83 Million | $61.45 Million | ▲ +29.9% |
| 2022 | -2.00x | $-97.24 Million | $-99.20 Million | $48.51 Million | — |